|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.40 EUR | -0.38% |
|
-1.86% | -15.37% |
| 12-11 | Merck KGaA's SpringWorks Gets UK Clearance for Plexiform Neurofibromas Therapy | MT |
| 12-11 | UK's MHRA approves mirdametinib to treat plexiform neurofibromas | RE |
Business description: Merck KGaA
- solutions and products for scientific and biotechnological research (42.1%);
- pharmaceutical products (40%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.9%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.7%), Switzerland (1.9%), Europe (22.6%), the United States (25.7%), North America (1.3%), China (13.5%), Asia/Pacific (19.6%), Latin America (7%), Middle East and Africa (3.7%).
Number of employees: 62,346
Sales by Activity: Merck KGaA
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Life Science | 7.53B | 9.05B | 10.44B | 9.36B | 9.01B |
Healthcare | 6.64B | 7.09B | 7.84B | 8.05B | 8.46B |
Electronics | 3.38B | 3.61B | 4.01B | 3.66B | 3.78B |
Corporate and Other | -18M | -62M | -61M | -77M | -91M |
Geographical breakdown of sales: Merck KGaA
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
USA | 4.64B | 5.25B | 6.3B | 5.91B | 5.65B |
Other Europe | 3.55B | 4.03B | 4.52B | 4.4B | 4.5B |
Asia-Pacific (Excluding China) | 3.74B | 4.09B | 4.48B | 4.18B | 4.14B |
China | 2.22B | 2.55B | 2.82B | 2.48B | 2.58B |
Latin America | 868M | 947M | 1.18B | 1.27B | 1.43B |
Germany | 1.5B | 1.66B | 1.53B | 1.42B | 1.41B |
Switzerland | 462M | 529M | 592M | 512M | 594M |
Middle East and Africa (MEA) | 361M | 404M | 516M | 535M | 590M |
North America (Excluding USA) | 191M | 225M | 294M | 287M | 263M |
Executive Committee: Merck KGaA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 30/04/2021 | |
| Director of Finance/CFO | 55 | 30/06/2023 | |
Laura Matz
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2021 |
David Weinreich
CTO | Chief Tech/Sci/R&D Officer | - | 27/08/2025 |
Constantin Fest
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: Merck KGaA
| Director | Title | Age | Since |
|---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | 25/04/2019 |
Jürgen Glaser
BRD | Director/Board Member | 63 | 30/04/2012 |
| Director/Board Member | 76 | 08/05/2014 | |
Gabriele Eismann
BRD | Director/Board Member | 64 | 08/05/2014 |
Dietmar Oeter
BRD | Director/Board Member | 59 | 08/05/2014 |
Alexander Putz
BRD | Director/Board Member | 49 | 08/05/2014 |
Sascha Held
BRD | Director/Board Member | - | 25/04/2019 |
| Chairman | 68 | 31/01/2024 | |
Renate Koehler
BRD | Director/Board Member | - | 25/04/2019 |
Anne Lange
BRD | Director/Board Member | - | 25/04/2019 |
Holdings: Merck KGaA
| Name | Equities | % | Valuation |
|---|---|---|---|
PRECIGEN, INC. 6.92% | 20,647,152 | 6.92% | 79,078,592 $ |
Company details: Merck KGaA
Group companies: Merck KGaA
| Name | Category and Sector |
|---|---|
Ridgefield Acquisition SARL | |
AZ Electronic Materials (Luxembourg) SARL
 AZ Electronic Materials (Luxembourg) SARL Produces photoresists, spin-on dielectrics and anti-reflective coatings | |
Merck Life Science Pvt Ltd.
 Merck Life Science Pvt Ltd. Manufactures and distributes medical and laboratory equipment | |
Merck Performance Materials Pvt Ltd.
 Merck Performance Materials Pvt Ltd. Produces and supplies specialty chemicals and functional materials for various applications | |
Merck Specialities Pvt Ltd.
 Merck Specialities Pvt Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals |
Pharmaceuticals: Major
|
Specialty & Advanced Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.38% | -1.86% | -16.12% | -36.55% | 60.15B | |
| +1.03% | +0.41% | +5.82% | -17.63% | 8.58B | |
| +0.50% | -1.77% | +29.60% | +5.55% | 7.32B | |
| -1.84% | -0.60% | +25.78% | +79.03% | 7.06B | |
| +0.86% | -0.26% | -2.34% | +116.07% | 5.91B | |
| -0.64% | +1.25% | +207.35% | +61.64% | 4.44B | |
| -0.87% | +0.06% | -12.77% | -6.82% | 2.84B | |
| +1.40% | +3.24% | +30.38% | +33.60% | 2.7B | |
| +0.87% | -1.80% | +19.19% | +45.66% | 2.5B | |
| +0.10% | -0.77% | -16.39% | +1.49% | 1.95B | |
| Average | +0.10% | -0.16% | +27.05% | +28.20% | 10.35B | |
| Weighted average by Cap. | -0.17% | -1.18% | +4.33% | -5.83% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
- Company Merck KGaA
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition